metformin aurobindo 1000 mg filmsko obložene tablete
aurobindo pharma limited - metformin - filmsko obložena tableta - metformin 780 mg / 1 tableta - metformin
metformin aurobindo 1000 mg filmsko obložene tablete
aurobindo pharma limited - metformin - filmsko obložena tableta - metformin 780 mg / 1 tableta - metformin
metformin aurobindo 500 mg filmsko obložene tablete
aurobindo pharma limited - metformin - filmsko obložena tableta - metformin 390 mg / 1 tableta - metformin
metformin aurobindo 850 mg filmsko obložene tablete
aurobindo pharma limited - metformin - filmsko obložena tableta - metformin 663 mg / 1 tableta - metformin
cetirizin lek 10 mg filmsko obložene tablete
lek d.d. - cetirizin - filmsko obložena tableta - cetirizin 8,4 mg / 1 tableta cetirizinijev diklorid - cetirizin
noviana 0,5 mg/0,1 mg filmsko obložene tablete
filmsko obložena tableta - noretisteron in estrogen
zaditen 0,25 mg/ml kapljice za oko, raztopina
laboratoires thea - ketotifen - kapljice za oko, raztopina - ketotifen 0,25 mg / 1 ml - ketotifen
zaditen sdu 0,25 mg/ml kapljice za oko, raztopina v enoodmernih vsebnikih
laboratoires thea - ketotifen - kapljice za oko, raztopina - ketotifen 0,25 mg / 1 ml - ketotifen
tagrisso
astrazeneca ab - osimertinib mesilate - karcinom, pljučni pljuč - druga zdravila z delovanjem na novotvorbe agenti, protein kinaza inhibitorji - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
zaditen sdu 0,25 mg/ml kapljice za oko, raztopina v enoodmernih vsebnikih
laboratoires thea - ketotifen - kapljice za oko, raztopina - ketotifen 0,25 mg / 1 ml - ketotifen